Search Within

Joachim Yahalom

  1. "Center for Hematologic Malignancies"
Formats
  1. Meeting Abstract (123)
  2. Journal Article (100)
  3. Book Section (17)
  4. Research Letter (4)
  5. Conference Paper (3)
  6. Review (1)
Groups
  1. Center for Hematologic Malignancies (248)
  2. Radiation Oncology, Department of (248)
  3. Survivorship Research (248)
  4. Department of Medicine (243)
  5. Hematologic Malignancies, Division of (243)
  6. Lymphoma (205)

More Groups

People
  1. Andrew Zelenetz (116)
  2. David Straus (82)
  3. Ariela Noy (71)
  4. Craig Moskowitz (71)
  5. Steven Horwitz (65)
  6. Maria Palomba (63)

More People

Years
  1. 2025 (3)
  2. 2024 (17)
  3. 2023 (28)
  4. 2022 (11)
  5. 2021 (13)
  6. 2020 (12)

More Years

Publications
  1. Blood (77)
  2. International Journal of Radiation Oncology, Biology, Physics (25)
  3. Hematological Oncology (20)
  4. Journal of Clinical Oncology (16)
  5. Journal of the National Comprehensive Cancer Network (14)
  6. British Journal of Haematology (9)

More Publications

Publishers
  1. American Society of Hematology (85)
  2. Elsevier Inc. (40)
  3. Wiley Blackwell (23)
  4. American Society of Clinical Oncology (16)
  5. Harborside Press (14)
  6. Nature Publishing Group (12)

More Publishers

Results (248)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genetic alterations in follicular lymphoma predict response to very low dose radiotherapy
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E.; Chan, A.; Lee, J.; Fregonese, B.; Hajj, C.; Cedarquist, G.; Hubbeling, H.; Ma, J.; Sarkar, R.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T‐cell therapy outcome
    Meeting Abstract

    Imber, B. S.; Silverman, E. A.; Leithner, D.; Hubbeling, H.; Shah, G. L.; Fregonese, B.; Sanin, B. W.; Tomas, A. A.; Parascondola, A.; Saldia, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Predictors of survival in patients with MALT lymphoma: A retrospective, case-control study
    Review

    Qi, S.; Liu, X.; Noy, A.; Lee, J.; Teckie, S.; Hajj, C.; Joffe, E.; Imber, B. S.; Yahalom, J.
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Bridging radiation rapidly and effectively cytoreduces high-risk relapsed/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell therapy
    Journal Article

    Hubbeling, H.; Silverman, E. A.; Michaud, L.; Tomas, A. A.; Shouval, R.; Flynn, J.; Devlin, S.; Wijetunga, N. A.; Tringale, K. R.; Batlevi, C.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting
    Journal Article

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S.; Kumar, A.; Matasar, M. J.; more...
    Cancers (2023)

    Fulltext@MSK | Save
  • Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma
    Journal Article

    Alarcon Tomas, A.; Fein, J. A.; Fried, S.; Flynn, J. R.; Devlin, S. M.; Fingrut, W. B.; Anagnostou, T.; Alperovich, A.; Shah, N.; Fraint, E.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era
    Research Letter

    Qualls, D.; Imber, B. S.; Okwali, M.; Hamlin, P. A.; Kumar, A.; Lahoud, O. B.; Matasar, M. J.; Noy, A.; Owens, C.; Zelenetz, A. D.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Radiotherapy for secondary CNS lymphoma: Patterns of utilization and clinical outcomes
    Meeting Abstract

    Cederquist, G. Y.; Tringale, K. R.; Hajj, C.; Hubbeling, H.; Fregonese, B.; Lee, J.; Scordo, M.; Grommes, C.; Yahalom, J.; Imber, B. S.
    Blood (2022)

    Fulltext@MSK | Save